Astellas Pharma Inc. (OTCMKTS:ALPMY) Sees Significant Drop in Short Interest

Astellas Pharma Inc. (OTCMKTS:ALPMY - Get Free Report) saw a large drop in short interest in February. As of February 15th, there was short interest totalling 47,200 shares, a drop of 49.0% from the January 31st total of 92,500 shares. Based on an average trading volume of 625,500 shares, the short-interest ratio is presently 0.1 days.

Astellas Pharma Stock Up 2.1 %

Shares of OTCMKTS:ALPMY traded up $0.20 during midday trading on Wednesday, hitting $9.90. The stock had a trading volume of 111,931 shares, compared to its average volume of 233,877. The company has a quick ratio of 0.80, a current ratio of 1.04 and a debt-to-equity ratio of 0.39. The business's 50-day simple moving average is $9.62 and its 200-day simple moving average is $10.73. The company has a market cap of $17.92 billion, a P/E ratio of -45.00 and a beta of 0.34. Astellas Pharma has a 12 month low of $9.05 and a 12 month high of $13.14.

Astellas Pharma (OTCMKTS:ALPMY - Get Free Report) last released its earnings results on Tuesday, February 4th. The company reported $0.30 earnings per share for the quarter. Astellas Pharma had a positive return on equity of 13.69% and a negative net margin of 3.10%. On average, sell-side analysts forecast that Astellas Pharma will post 0.42 earnings per share for the current fiscal year.

About Astellas Pharma

Astellas Pharma Inc manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer.